Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $62000.0.

  • Aytu Biopharma's Income towards Parent Company rose 10500.4% to $62000.0 in Q2 2025 from the same period last year, while for Dec 2025 it was $116000.0, marking a year-over-year increase of 10869.57%. This contributed to the annual value of $620000.0 for FY2025, which is 11865.22% up from last year.
  • According to the latest figures from Q2 2025, Aytu Biopharma's Income towards Parent Company is $62000.0, which was up 10500.4% from $54000.0 recorded in Q1 2025.
  • In the past 5 years, Aytu Biopharma's Income towards Parent Company registered a high of $381000.0 during Q3 2024, and its lowest value of -$53.3 million during Q1 2022.
  • For the 5-year period, Aytu Biopharma's Income towards Parent Company averaged around -$9.6 million, with its median value being -$1.9 million (2023).
  • As far as peak fluctuations go, Aytu Biopharma's Income towards Parent Company crashed by 54679.52% in 2021, and later surged by 15888.72% in 2024.
  • Quarter analysis of 5 years shows Aytu Biopharma's Income towards Parent Company stood at -$11.5 million in 2021, then skyrocketed by 42.04% to -$6.7 million in 2022, then surged by 87.46% to -$839000.0 in 2023, then skyrocketed by 114.66% to $123000.0 in 2024, then crashed by 49.59% to $62000.0 in 2025.
  • Its Income towards Parent Company was $62000.0 in Q2 2025, compared to $54000.0 in Q1 2025 and $123000.0 in Q4 2024.